News | October 25, 2023
Sumitomo Pharma announces authorization in Canada of Orgovyx for treatment prostate cancer
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
Syngene gains access to ERS Genomics' foundational CRISPR/Cas9 patent portfolio, ushering in a new era of technical innovation in India for its global partners
New Molecular biology lab launched, AIIA increased its work scope in form of MoUs
Investment is additive to KKR’s existing health care growth strategy
The vaccine further advances Pfizer’s vaccine portfolio and builds on more than 20 years of expertise and knowledge in the prevention of meningococcal disease
Three-point improvement achieved in Sex Ratio at Birth from 904 in 2017-19 to 907 in 2018-20
hey were educated about the 7- step hand-washing technique trainings
Pant delivers keynote address at National Conclave on “Augmented Zoonotic Diseases Surveillance at Human – Wildlife Interface”
New effective carrier systems for drug delivery in different dosage applications including oral, topical & parenteral
Glenmark's Zita portfolio of medicines have been benefiting around 1.75 million Type 2 diabetic patients annually
Subscribe To Our Newsletter & Stay Updated
